A randomized study of two interferon- beta treatments in relapsing–remitting multiple sclerosis

The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration

2001 • 3,719 citations

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1998 • 2,049 citations

Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

1993 • 2,032 citations

Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

1993 • 1,908 citations

Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines: Table 1.

2002 • 812 citations

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)

2002 • 557 citations

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

2003 • 370 citations

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis

1997 • 234 citations

Immunogenicity of interferon-? in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administration

2000 • 223 citations

Benefits of high-dose, high-frequency interferon beta-1a in relapsing–remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial

2005 • 104 citations

The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis

2000 • 28 citations